← Research LibraryThe BriefFY2025 20-F · headline figures audited against SEC data
Revenue grew 6.2% to €43.63B on Dupixent; net income rose 40.5% to €7.81B, helped by a €2.6bn gain on selling control of Opella.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +6.2% to €43.63B, led by DupixentOK
- Profitability — Operating margin 14.5%, down 311 bps on impairments; net income €7.81BWatch
- Cash — Free cash flow €7.21B, +22.5%OK
- Balance sheet — Total equity €71.38B, -7.9%Note
- Capital — Dividend €4.12 per share proposed; up to €5bn of buybacks authorisedNote
- Geography — 50.8% of net sales from the United StatesNote
Business
Sanofi is a French maker of medicines and vaccines. Its largest product is Dupixent, whose 2025 net sales were €11,538m in the US, €1,957m in Europe and €2,219m in the rest of the world. In 2025 it sold a 50.0% controlling stake in Opella, its consumer healthcare business, to CD&R and kept a 48.2% stake.
Latest filings
- 6-K · Company announcement (foreign filer)2026-10-01
- 6-K · Company announcement (foreign filer)2026-09-17
- 6-K · Company announcement (foreign filer)2026-08-06
- 6-K · Company announcement (foreign filer)2026-07-30
- 6-K · Company announcement (foreign filer)2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Sanofi, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.